Hepatitis C and progression of HIV disease

JAMA

Volumn 288, Issue 2, 2002, Pages 199-206

  Sulkowski, Mark S ^a   Moore, Richard D ^a   Mehta, Shruti H ^a   Chaisson, Richard E ^a   Thomas, David L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; COMORBIDITY; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

EID: 0037055011     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.2.199     Document Type: Article

References (46)

1. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus
2. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995
3. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
4. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection
5. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
6. Natural history of hepatitis C virus infection in multitransfused hemophiliacs
7. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections
8. The natural history of hepatitis C virus infection
9. Determinants of the quantity of hepatitis C virus RNA
10. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
11. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?
12. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
13. Hepatitis C in HIV-infected patients with and without AIDS
14. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS)
15. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS
16. Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease
17. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users
18. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection
19. Racial differences in the use of drug therapy for HIV disease in an urban community
20. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
21. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
22. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
23. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C
24. What's the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes
25. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
26. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
27. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
28. Injecting drug users' adherence to HIV antiretroviral treatments
29. Self-reported antiretroviral therapy in injection drug users
30. Barriers to use of free antiretroviral therapy in injection drug users
31. A comparison of exposure groups in the EuroSIDA study
32. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection
33. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
34. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
35. Declining morbidity and mortality among patients with advanced human immunodeficiency infection
36. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection
37. Problems with proper completion and accuracy of the cause-of-death statement
38. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA
39. Pre-AIDS mortality from natural causes associated with HIV disease progression
40. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
41. Diagnosis of hepatitis C
42. Infection with GB virus C and reduced mortality among HIV-infected patients
43. Effect of coinfection with GB virus C on survival among patients with HIV infection
44. The association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection
45. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia
46. Prevalence and prognostic significance of infection with TT virus in patients infected with human immunodeficiency virus